J&J

Explore the latest insights on J&J and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of J&J’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Explore the latest insights on J&J and its impact on China's pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of J&J's developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

EMA's CHMP Backs Indication Extension for Johnson & Johnson's TALVEY – Talquetamab Combination Moves Toward Earlier‑Line Relapsed/Refractory Multiple Myeloma
CompanyDrug

EMA’s CHMP Backs Indication Extension for Johnson & Johnson’s TALVEY – Talquetamab Combination Moves Toward Earlier‑Line Relapsed/Refractory Multiple Myeloma

Johnson & Johnson (J&J; NYSE: JNJ) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of an indication…

Ascentage Pharma Signs Strategic Collaboration with Suzhou University and Its First Affiliated Hospital – Tripartite Partnership Targets Hematologic Oncology Innovation

Ascentage Pharma Signs Strategic Collaboration with Suzhou University and Its First Affiliated Hospital – Tripartite Partnership Targets Hematologic Oncology Innovation

FDA Approves Roche's Enspryng for Thyroid Eye Disease – Satralizumab Becomes First and Only At‑Home Subcutaneous TED Treatment

FDA Approves Roche’s Enspryng for Thyroid Eye Disease – Satralizumab Becomes First and Only At‑Home Subcutaneous TED Treatment

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Company

Sanofi Eyes Blockbuster Potential with 12 Pipeline Assets, Projects EUR 10 Billion in Annual Sales by 2030

Company

J&J Forecasts 5-7% CAGR Through 2030, Driven by Innovative Medicine and Device Growth

CompanyDeals

Johnson & Johnson Acquires Laminar for $400 Million to Enhance Heart Rhythm Solutions

CompanyDrug

Janssen Submits Indication Extension Application to FDA for Rybrevant in NSCLC Treatment

CompanyDrug

Janssen Presents Real-World Data on Tremfya’s Efficacy in Treatment-Resistant Psoriatic Arthritis

CompanyDeals

CIIE 2023: Danaher, Boehringer-Ingelheim, Merck, J&J, BeiGene, and Fosun Pharma Announce China Partnerships

CompanyDrug

Janssen’s Nipocalimab Shows Promising Results in Phase II Rheumatoid Arthritis Trial

CompanyDeals

GSK Acquires Global Rights to Janssen’s Hepatitis B Antiviral JNJ-3989 in $1 Billion Deal

Show More